AVTX_OUT_1 [2025-03-25 10:58:23 -0400] 1890 Bytes | 520 tokens | Cum: 520 tkns (6.50% of 8k)
==========================================================================

Alright, let’s light it up, because it's 10:58:21 AM on Tue Mar 25, 2025 -0400, and I'm charging into Avalo Therapeutics (AVTX), popping from 7.63 to 9.23. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

Here's the first list of news for Avalo Therapeutics:

C1 - Mar-20-25 07:00AM - Avalo Reports 2024 Financial Results and Recent Business Updates
C2 - Feb-24-25 07:00AM - Avalo Therapeutics to Participate in Upcoming Investor Conferences
C3 - Feb-04-25 08:00AM - Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
C4 - Jan-02-25 07:00AM - Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
C5 - Dec-20-24 06:50AM - Avalo Therapeutics initiated with a Buy at BTIG
C6 - Nov-12-24 07:00AM - Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
C7 - Nov-11-24 07:00AM - Avalo Therapeutics to Present at Upcoming Investor Conferences
C8 - Nov-07-24 07:00AM - Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Avalo Therapeutics (AVTX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

AVTX_OUT_3 [2025-03-25 10:58:26 -0400] 1044 Bytes | 302 tokens | Cum: 824 tkns (10.30% of 8k)
==========================================================================

Showing C1 (chunk 1 of 8): C1:
**Avalo Reports 2024 Financial Results and Recent Business Updates**
Date: Mar-20-25 07:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/20/3046094/0/en/Avalo-Reports-2024-Financial-Results-and-Recent-Business-Updates.html

March 20, 2025 07:00 ET| Source:Avalo TherapeuticsAvalo Therapeutics

WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024.

“2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time,” said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. “In March 2024, we acquired AVTX-009, a promising monoclonal antibody targeting interleukin-

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

AVTX_OUT_5 [2025-03-25 10:58:28 -0400] 1045 Bytes | 227 tokens | Cum: 1053 tkns (13.16% of 8k)
==========================================================================

Showing C1 (chunk 2 of 8): 1β. We filed our IND application with the FDA, designed and launched the Phase 2 LOTUS trial in hidradenitis suppurativa (“HS”) and rapidly progressed its initiation, including IND activation in July and enrollment of the first patient in October. Our primary focus in 2025 is executing the LOTUS trial to release data in 2026, while exploring broader applications for AVTX-009 and announcing a second indication.”

Recent Corporate Highlights and Upcoming Anticipated Milestones:

Consolidated Balance Sheets(In thousands, except share and per share data)

The consolidated balance sheets as of December 31, 2024 and 2023 have been derived from the audited financial statements, but do not include all of the information and footnotes required by accounting principles accepted in the United States for complete financial statements.

Consolidated Statements of Operations(In thousands, except per s

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

AVTX_OUT_7 [2025-03-25 10:58:30 -0400] 846 Bytes | 259 tokens | Cum: 1314 tkns (16.43% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-24T05:34:10Z - Wedbush Research Analysts Lift Earnings Estimates for AVTX...
A2 - 2025-03-24T05:33:54Z - Equities Analysts Set Expectations for AVTX Q1 Earnings...
A3 - 2025-03-22T10:48:41Z - Q1 EPS Estimates for Avalo Therapeutics Lifted by Wedbush...
A4 - 2025-03-21T16:19:24Z - Avalo Therapeutics (NASDAQ:AVTX) Given Neutral Rating at HC Wainwright...
A5 - 2025-03-21T16:08:55Z - Avalo Therapeutics (NASDAQ:AVTX) Given Outperform Rating at Wedbush...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

AVTX_OUT_9 [2025-03-25 10:58:31 -0400] 1038 Bytes | 295 tokens | Cum: 1611 tkns (20.14% of 8k)
==========================================================================

Showing A1 (chunk 1 of 6): A1:
**Wedbush Research Analysts Lift Earnings Estimates for AVTX**Date: 2025-03-24Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/wedbush-research-analysts-lift-earnings-estimates-for-avtx-2025-03-24/Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) - Equities researchers at Wedbush raised their Q2 2025 earnings per share (EPS) estimates for Avalo Therapeutics in a report released on Thursday, March 20th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($1.25) per share for the quarter, up from their prior forecast of ($1.40). Wedbush currently has a "Outperform" rating and a $18.00 target price on the stock. The consensus estimate for Avalo Therapeutics' current full-year earnings is ($19.07) per share. Wedbush also issued estimates for Avalo Therapeutics' Q3 2025 earnings at

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

AVTX_OUT_11 [2025-03-25 10:58:33 -0400] 924 Bytes | 279 tokens | Cum: 1892 tkns (23.65% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-02T12:00:00Z - Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
B2 - 2024-11-12T12:00:00Z - Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
B3 - 2024-11-11T12:00:00Z - Avalo Therapeutics to Present at Upcoming Investor Conferences
B4 - 2024-07-16T11:05:45Z - Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer - GlobeNewswire
B5 - 2024-06-24T20:01:00Z - Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
B6 - 2024-06-17T11:30:00Z - Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

AVTX_OUT_13 [2025-03-25 10:58:37 -0400] 786 Bytes | 203 tokens | Cum: 2097 tkns (26.21% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/11/12/2978861/0/en/Avalo-Therapeutics-Receives-69-4-Million-in-Proceeds-from-the-Full-Exercise-of-Private-Placement-Warrants.htmlAvalo Therapeutics received $69.4 million in proceeds from the full exercise of warrants issued in a March 2024 private placement, bringing the total gross proceeds from the transaction to $185 million. The company plans to use the funds to expand its AVTX-009 program into additional inflammatory indications.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

AVTX_OUT_15 [2025-03-25 10:58:39 -0400] 1068 Bytes | 294 tokens | Cum: 2457 tkns (30.71% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-20 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our CONS financial statements and related notes i...

S2 - 2025-03-20 8-K Item 2.02 Results of Oper and Fin Cond.

On March 20, 2025, Avalo Therapeutics, Inc. (the Company) issued a press release announcing its financial results for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is...

S9 - 2024-11-07 10-Q PART I - FIN INFO

Item 1. Fin Stmnts.

AVALO THERAPEUTICS, INC. and SUBSIDIARIES

Condensed Cons Balance Sheets

(In thousands, except share and per share data)

September 30, 2024 December 31, 2023 (unaudited) Assets Curr assets: Cash and...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

AVTX_OUT_17 [2025-03-25 10:58:40 -0400] 1038 Bytes | 200 tokens | Cum: 2659 tkns (33.24% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review the Risk Factors section in this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

AVTX_OUT_19 [2025-03-25 10:58:42 -0400] 1038 Bytes | 254 tokens | Cum: 2915 tkns (36.44% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): analysis.

Overview

Avalo Therapeutics, Inc. (the Company, Avalo or we) is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalos lead asset is AVTX-009, an anti-IL-1 monoclonal antibody (mAb), targeting inflammatory diseases.

Our initial focus in 2024 was augmenting our immunology pipeline and securing financing to develop our pipeline. In March 2024, we acquired our lead asset, AVTX-009, through our acquisition of AlmataBio, Inc. (AlmataBio). Concurrently, we executed a private placement of $185 million, including initial upfront investment of $115.6 million received in March 2024. We received the remaining $69.4 million of gross proceeds in the fourth quarter of 2024 upon the full exercise of the warrants issued as part of the transaction. Immediately following the acquisition of AVTX-009, our focus shifted to executing operationally on t

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

AVTX_OUT_21 [2025-03-25 10:58:44 -0400] 1038 Bytes | 244 tokens | Cum: 3161 tkns (39.51% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): he development of AVTX-009 for the treatment of hidradenitis suppurativa (HS). This included activation of the Investigational New Drug (IND) application in July 2024 and enrolling the first patient in our Phase 2 LOTUS trial in October 2024 (the LOTUS Trial). The LOTUS Trial is a global study designed to enroll 180 adults with HS to assess the efficacy and safety of convenient subcutaneous bi-weekly and monthly dosing regimens of AVTX-009, compared to placebo, with topline data expected in 2026.

Our focus in 2025 is continuing to execute operationally on the development of AVTX-009, most notably the progression of the LOTUS Trial. We are committed to executing the LOTUS Trial effectively and efficiently, as well as exploring AVTX-009s potential broad applications for other immune-mediated diseases as we work toward the announcement of our second indication.

Managements primary evalu

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

AVTX_OUT_23 [2025-03-25 10:58:51 -0400] 1038 Bytes | 234 tokens | Cum: 3397 tkns (42.46% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): ation of Avalos success is the ability to progress its programs towards commercialization or opportunistically out-licensing rights to indications or geographies. We believe the ability to achieve the next anticipated milestone as presented in the section entitled Business in Item 1 of this Annual Report on Form 10-K represents our most immediate evaluation point as to the progression of our pipeline.

2024 Financial Operations Overview

As of December 31, 2024, Avalo had $134.5 million in cash and cash equivalents, representing a $127.1 million increase compared to December 31, 2023. During the year, we raised approximately $175.8 million of net proceeds from a private placement and the subsequent exercise of warrants issued in the private placement. Net cash used in operating activities were $49.1 million for the year ended December 31, 2024, which includes $12.5 million of milestone

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

AVTX_OUT_25 [2025-03-25 10:59:11 -0400] 5139 Bytes | 1476 tokens | Cum: 4990 tkns (62.38% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+---------------------+----------------------+------------------------+------------------------+------------------------+
| Volume: 148,423 | SMA50: 21.98% | Market Cap: 97.72M | Option/Short: No / Yes | Sales past 5Y: 9.56% | Sales Surprise: - |
+--------------------+---------------------+----------------------+------------------------+------------------------+------------------------+
| Avg Volume: 75.09K | SMA200: -6.50% | Shs Outstand: 10.47M | Short Float: 1.08% | Employees: 23 | EPS Surprise: -274.33% |
+--------------------+---------------------+----------------------+------------------------+------------------------+------------------------+
| Rel Volume: 8.68 | Perf Week: 17.84% | Shs Float: 8.40M | Short Ratio: 1.21 | Debt/Eq: 0.02 | P/E: - |
+--------------------+---------------------+----------------------+------------------------+------------------------+------------------------+
| RSI (14): 63.59 | Perf Month: 13.04% | Inst Own: 58.11% | Short Interest: 0.09M | Sales Y/Y TTM: -77.09% | Earnings: Mar 20 BMO |
+--------------------+---------------------+----------------------+------------------------+------------------------+------------------------+
| ATR (14): 0.90 | Perf Quarter: 0.84% | Insider Own: 19.68% | Beta: 0.78 | ROE: -50.06% | |
+--------------------+---------------------+----------------------+------------------------+------------------------+------------------------+
| SMA20: 22.01% | Index: - | Insider Trans: 0.05% | Sales Q/Q: -66.37% | ROI: -108.44% | |
+--------------------+---------------------+----------------------+------------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Avalo Therapeutics, Inc. (AVTX) by Doyle Mittie (Chief Medical Officer) on 2025-01-28
- Stock Option (Right to Buy): 155000 shares at $0 (D)

Inside Trans: Avalo Therapeutics, Inc. (AVTX) by NEIL GARRY ARTHUR (CEO and Chairman of the Board) on 2025-01-28
- Stock Option (Right to Buy): 411000 shares at $0 (D)

Inside Trans: Avalo Therapeutics, Inc. (AVTX) by Sullivan Christopher Ryan (Chief Financial Officer) on 2025-01-28
- Stock Option (Right to Buy): 163000 shares at $0 (D)

Inside Trans: Avalo Therapeutics, Inc. (AVTX) by VARKI PAUL (Chief Legal Officer) on 2025-01-28
- Stock Option (Right to Buy): 100000 shares at $0 (D)

No transactions recorded.

Inside Trans: Avalo Therapeutics, Inc. (AVTX) by Riley Jennifer (Chief Strategy Officer) on 2025-01-01
- Stock Option (Right to Buy): 150000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: Avalo Therapeutics, Inc. Common Stock
Market Cap: 96929700.00000001
Shares Outstanding: 10500000
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 441000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -35129000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 8.83
Average Volume: 100846.91
30-Day High: 8.83
30-Day Low: 6.6

[Detailed Financials: TTM 2024]
- Total Assets: $150,732,000.0
- Total Liabilities: $17,700,000.0
- Total Equity: $133,032,000.0
- Current Assets: $138,890,000.0
- Current Liabilities: $6,960,000.0

[Income Statement: TTM 2024]
- Revenue: $441,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -7.94

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $127,149,000.0

[Detailed Financials: FY 2024]
- Total Assets: $150,732,000.0
- Total Liabilities: $17,700,000.0
- Total Equity: $133,032,000.0
- Current Assets: $138,890,000.0
- Current Liabilities: $6,960,000.0

[Income Statement: FY 2024]
- Revenue: $441,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -7.94

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $127,149,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

AVTX_OUT_27 [2025-03-25 10:59:16 -0400] 676 Bytes | 167 tokens | Cum: 5416 tkns (67.70% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

AVTX_IN_29 [2025-03-25 10:59:16 -0400] 126 Bytes | 29 tokens | Cum: 5535 tkns (69.19% of 8k)
==========================================================================

====================================
[2025-03-25 07:59:16] # Analysis Completed
Elapsed Time: 55.96 seconds